Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024
Cash flows from operating activities:
Net loss	$ (8,843)	$ (4,602)
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	2,663	3,464
Amortization of acquisition related intangible assets	345	657
Non-cash operating lease cost	1,067	975
Stock-based compensation expense	5,411	7,481
Deferred income taxes	15	210
Provision for credit losses	133	103
Provision for inventory	3,842	2,738
Interest income on notes receivable	(345)	0
Gain on sale of assets	(505)	0
Changes in operating assets and liabilities:
Accounts receivable	659	1,859
Inventories	2,252	(8,812)
Prepaid expenses, other current and long-term assets	797	726
Accounts payable	(1,066)	549
Operating lease liabilities	(1,045)	(938)
Accrued expenses, other current and long-term liabilities	(5,251)	(4,934)
Income taxes	(448)	(671)
Net cash provided by (used in) operating activities	(319)	(1,195)
Cash flows from investing activities:
Proceeds from sale of Parcus Medical, net	4,496	0
Proceeds from sale of intangible assets	600	0
Notes receivable	328	0
Purchases of property and equipment	(4,291)	(5,211)
Net cash provided by (used in) investing activities	1,133	(5,211)
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]
Proceeds from employee stock purchase program	261	411
Cash paid for tax withheld on vested restricted stock awards	(1,549)	(2,501)
Proceeds from exercises of equity awards	0	76
Repurchases of common stock	(3,971)	(1,370)
Net cash used in financing activities	(5,259)	(3,384)
Exchange rate impact on cash	453	(255)
Decrease in cash and cash equivalents	(3,992)	(10,045)
Cash and cash equivalents at beginning of period	57,159	72,867
Cash and cash equivalents at end of period	53,167	62,822
Supplemental disclosure of cash flow information:
Purchases of property and equipment included in accounts payable and accrued expenses	$ 820	$ 585